Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sonoma Pharmaceuticals (SNOA) Equity Average (2016 - 2025)

Sonoma Pharmaceuticals has reported Equity Average over the past 15 years, most recently at $3.6 million for Q4 2025.

  • For Q4 2025, Equity Average fell 29.38% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $3.6 million, down 29.38%, while the annual FY2025 figure was $5.3 million, 25.27% down from the prior year.
  • Equity Average for Q4 2025 was $3.6 million at Sonoma Pharmaceuticals, down from $3.9 million in the prior quarter.
  • Over five years, Equity Average peaked at $11.3 million in Q4 2021 and troughed at $3.6 million in Q4 2025.
  • A 5-year average of $6.5 million and a median of $6.4 million in 2022 define the central range for Equity Average.
  • On a YoY basis, Equity Average climbed as much as 66.83% in 2022 and fell as far as 44.41% in 2022.
  • Year by year, Equity Average stood at $11.3 million in 2021, then crashed by 44.41% to $6.3 million in 2022, then fell by 1.69% to $6.2 million in 2023, then dropped by 17.34% to $5.1 million in 2024, then decreased by 29.38% to $3.6 million in 2025.
  • Business Quant data shows Equity Average for SNOA at $3.6 million in Q4 2025, $3.9 million in Q3 2025, and $4.2 million in Q2 2025.